LOUGHBOROUGH, England(BUSINESS WIRE)
Results of recent clinical trials carried out on type 1 diabetics by
Nemaura Pharma using its Memspatch Insulin Micro-needle Device (IMD)
will come as a relief to those who fear needles and injections, a
condition medically known as trypanophobia, affecting 10 percent of the
Nemaura's Memspatch IMD compared favourably against a commonly-use
marketed Pen Injector (PI). The single-site clinical study involving 18
Type 1 diabetic patients took place over two periods, with a pain
assessment performed on each visit to evaluate the severity of the pain.
The Numeric Pain Rating Score system 0 10 was used; which scores no
pain at 0, through to 10 indicating the most intense pain sensation
imaginable. Patients were asked to record their experience of the
respective IMD and PI devices and to think about the intensity,
sharpness and itchiness of the pain immediately after administration.
Whilst pain intensity and sharpness inflicted by the PI reached 5 for
several patients, the Memspatch IMD recorded 0 or 1 when applied to the
arm or thigh.
These major reductions in pain levels are a result of the novel approach
Nemaura has taken to drug delivery systems. The Memspatch IMD is held
flat against the skin, with skin-penetration confined to a depth of 2mm
to 4mm, which is less than half the usual 9mm depth for pen injector
needles. Insulin delivery through shallow micro-needles requires little
training or basic skills, making self-medication much easier.
Commenting on the study results, Nemaura CEO Dr Faz Chowdhury said:
Needle phobia is a major barrier to health. We have looked carefully at
the human factors restricting diabetics wanting to self-administer
insulin, and have developed the Memspatch IMD to avoid puncture pain,
and to improve treatment compliance. Over 50 percent of adults with Type
2 Diabetes delay starting insulin due to needle fear, and over 90
percent feel fear reactions every time they inject. So we would
encourage the take-up of Memspatch IMD technology to help diabetics
better manage their condition.
Further Memspatch tests are planned later this year on a broad range of
other medicines alongside insulin, as Nemaura moves towards commercial
partner agreements on multiple medical conditions.
In 2016, Nemaura received Frost & Sullivan recognition of its advanced
micro-needle capability in skin drug delivery. Nemaura aims to be one of
the leading pharmaceutical technologists in this fast growing market,
which is expected to be worth 33billion by 2018.
Founded in 2005, Nemaura has patents secured or pending across multiple
patent families and now employs over 25 medical device technologists and
bio scientists based on the Loughborough University Science and
(Aronson R, DIABETES TECH & THERAP 2012 14(8):741-7; Kruger DF Diabetes
About Nemaura Pharma
Founded in 2005, Nemaura Pharma is a private specialist biotech company
with headquarters and research facilities in the Advanced Technology
Centre on the Loughborough University Science and Enterprise Park
(LUSEP) in the United Kingdom.
The company employs multi-disciplinary teams of scientists and engineers
working in cutting-edge innovative drug formulation and medical device
technologies designed to radically improve the way drugs are
administered through the skin. It has patents secured or pending in
multiple countries across numerous patent families.
The company has secured over 25m (over $30m) in licensing and
development payments, and private investment. In addition, Nemaura has
been awarded five highly competitive British Government grants, and the
Frost & Sullivan 2016 Enabling Technology Leadership Award in
Transdermal Drug Delivery.
Cautionary Statement Regarding Forward-Looking
The statements in this press release that are not historical facts may
constitute forward-looking statements that are based on current
expectations and are subject to risks and uncertainties that could cause
actual future results to differ materially from those expressed or
implied by such statements.
View source version on businesswire.com: http://www.businesswire.com/news/home/20170518005572/en/
(0) 7773 288342
+ 44 (0)1509 222 912
Source: Nemaura Pharma